GFAP and Alzheimer disease: Strong potential of plasma P‐tau181, GFAP, and NfL as biomarkers for AD and for differentiation of AD from FTD was recently confirmed in an unselected clinical cohort,51 indicating the potential of our neurocognitive blood test visualization tool to be informative in the real‐world clinical setting.